ATS View
한국어

Cell Biotech KRX:049960KOSDAQ

쎌바이오텍 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h4
Articles, 7 days8
DART filings, 7 days0
Articles tracked8since Sep 11

In Q2 2026, Cell Biotech reported revenue of ₩15.8bn, up 32.8% year on year, and operating profit of ₩1.6bn. Cell Biotech (쎌바이오텍) appeared in 8 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 8 articles. It was most often mentioned alongside Chong Kun Dang Pharmaceutical and Yuhan.

Cell Biotech quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩15.8bn+32.8%₩1.6bn₩3.6bn
Q1 2026₩14.6bn+30.0%₩3.2bn₩5.4bn
Q4 2025 derived₩14.6bn+20.4%₩3.1bn₩4.4bn
Q3 2025₩15.4bn+26.3%₩2.2bn₩3.4bn
Q2 2025₩11.9bn-5.2%₩1.3bn₩213m
Q1 2025₩11.2bn-13.9%₩1.4bn₩2.1bn
Q4 2024 derived₩12.2bn-18.1%₩1.1bn₩6.9bn
Q3 2024₩12.2bn-11.0%₩2.1bn₩969m

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Cell Biotech top stories 2 weeks, by number of outlets

  1. 1
    쎌바이오텍, 특허 유산균 2종 '간 지방 축적 억제' 기전 확인
    3 outlets · 3 articlesFirst report Sep 14 14:01 파이낸셜뉴스
  2. 2
    쎌바이오텍 듀오락 CBT 유산균, ‘지방간 개선’ 가능성 확인
    2 outlets · 2 articlesFirst report Sep 14 09:08 매일일보
  3. 3
    쎌바이오텍 듀오락 복합균주, ‘체지방 감소’ 넘어 ‘지방간 개선’ 효과 확인
    1 outlets · 1 articlesFirst report Sep 14 08:33 헤럴드경제
  4. 4
    [이BIO] 종근당·유한양행·쎌바이오텍 外
    1 outlets · 1 articlesFirst report Sep 14 10:16 프라임경제YuhanChong Kun Dang Pharmaceutical
  5. 5
    쎌바이오텍, 특허 유산균으로 지방간 개선 가능성 확인…간 지방 41.1%↓
    1 outlets · 1 articlesFirst report Sep 14 11:23 EBN

Latest Cell Biotech news Korean headlines